Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Novel selinexor triplet and quadruplet regimens (SNd, SPEd, SBd, SDPd): Results from the Phase 1b/2 STOMP multiple myeloma trial
Noa Biran, MD (she/her/hers)
Associate Professor of Medicine
Hackensack Meridian Health School of Medicine; The John Theurer Cancer Center
Hackensack, New Jersey, United States